According to new data from the phase III IMpower010 trial, adjuvant atezolizumab improves overall survival compared with best supportive care for some patients with operable non–small cell lung cancer. These results build on previous study findings, in which the immune checkpoint inhibitor, given after surgery and adjuvant chemotherapy, was shown to significantly decrease the likelihood of disease progression.

中文翻译：

---

Atezolizumab 辅助治疗在 NSCLC 中占有一席之地

根据 III 期 IMpower010 试验的新数据，与最佳支持治疗相比，辅助 atezolizumab 可以改善一些可手术非小细胞肺癌患者的总体生存率。这些结果建立在之前的研究结果的基础上，其中在手术和辅助化疗后给予免疫检查点抑制剂被证明可以显着降低疾病进展的可能性。